Sidra Medicine Signs MoU with Vitafluence.ai to Advance AI-Driven Healthcare Innovation

Enhancing Qatar’s healthcare landscape through advanced AI collaboration

20 April 2025, Doha, Qatar – Sidra Medicine, a member of Qatar Foundation, has signed a Memorandum of Understanding (MOU) with Germany-based Vitafluence.ai GmbH and its Swiss venture studio, EmpathicAI.Life, to explore potential collaborations in the field of artificial intelligence (AI) and digital health innovation.

The MoU outlines a framework for a three-year collaboration focused on the joint development of initiatives to advance AI-powered healthcare delivery as well as foster innovation within Sidra Medicine’s academic medical ecosystem. The agreement will set the groundwork for pilot programs, knowledge exchange, and co-development of digital solutions designed to support clinical decision-making and personalize patient care.

The MoU was signed by Dr. Iyabo Tinubu-Karch, CEO of Sidra Medicine and Dr. Peter O. Owotoki, Co-Founder of Vitafluence.ai. The signing ceremony was attended by Her Excellency Florence Tinguely Mattli, the Ambassador of Switzerland to the State of Qatar; Ms. Sarra Messaoudi, Economic & Commercial Officer, Swiss Business Hub Middle East-Qatar; as well as Prof. Khalid Fakhro, Chief Research Officer; Mr. Samuel Lock, Executive Director of Commercial Development and Ms. Marla Beerens, Director – Research Operations, Innovation and Strategy, Sidra Medicine.

Dr. Iyabo Tinubu-Karch, CEO of Sidra Medicine said: “Our joint research, clinical and medical education programs are designed to embrace emerging technologies that can revolutionize diagnostics, treatment and patient care. Working with Vitafluence.ai gives us the opportunity to explore a range of AI-driven applications, including predictive modeling, AI-assisted diagnostics, and tailored treatment pathways, that align with our mission of delivering world-class precision medicine for our patients.”

Vitafluence.ai brings deep expertise in developing proprietary AI models and platforms that power data-driven decision-making in healthcare and life sciences. Working in tandem with EmpathicAI’s venture incubation capabilities, the collaboration will evaluate how cutting-edge technologies can be adapted to the specific needs of Sidra Medicine’s clinical and research environment.

Dr. Peter O. Owotoki, Co-Founder of Vitafluence.ai GmbH, said: “We are truly excited to partner with Sidra Medicine as part of this innovative journey. This collaboration represents an incredible opportunity to contribute to Qatar’s ambitious vision for medical and digital health advancement, and most importantly, to work together in delivering impactful outcomes for women and children.”

Vitafluence and EmpathicAI Life will collaborate closely with Sidra Medicine’s clinical and operational teams to ensure that all initiatives uphold the highest standards of safety, ethics, and patient-centered care. The partnership lays the groundwork for introducing cutting-edge digital health solutions into Sidra Medicine’s ecosystem, driving forward its commitment to innovation and excellence in care.

Sidra Medicine will be exploring the transformative role of artificial intelligence in advancing global healthcare at its upcoming AI & Medicine 2025 conference from 23-26 April 2025. For more details, please visit: www.sidra.org.